Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | FBP1 | P09467 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | RARA | P10276 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL199971 | 1.00 | ALDH1A1 (0.58) | ALDH1A1FBP1TP53TSHRTDP1 | |
| SCHEMBL7564116 | 1.00 | ALDH1A1 (0.58) | ALDH1A1FBP1TP53TSHRTDP1 | |
| Oxirane SCHEMBL29253108 | 0.90 | ALDH1A1 (0.48) | ALDH1A1FBP1TP53TSHRTDP1 | |
| SCHEMBL12791487 | 0.89 | TRPA1 (0.58) | ALDH1A1FBP1TP53TSHRTDP1 | |
| Anethole SCHEMBL30697265 | 0.87 | XDH (0.71) | ALDH1A1TP53TSHRTDP1KMT2A | |
| SCHEMBL9681086 | 0.85 | ALDH1A1 (0.68) | ALDH1A1FBP1TP53TSHRTDP1 | |
| SCHEMBL9339856 | 0.85 | ALDH1A1 (0.68) | ALDH1A1FBP1TP53TSHRTDP1 | |
| SCHEMBL69167 | 0.85 | ALDH1A1 (0.68) | ALDH1A1FBP1TP53TSHRTDP1 | |
| SCHEMBL2615887 | 0.85 | ALDH1A1 (0.68) | ALDH1A1FBP1TP53TSHRTDP1 | |
| SCHEMBL9681088 | 0.85 | ALDH1A1 (0.68) | ALDH1A1FBP1TP53TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102887992-A | Polyester/polyethylene glycol block copolymer containing side cinnamoyl group and application thereof | UNIV TIANJIN | 2013-01-23 | — | — | CN | claimed |
| EP-0079639-B1 | A NEW ANTI-INFLAMMATORY DRUG | SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A. (IT) | 1985-07-24 | — | — | EP | claimed |
| WO-2023215514-A2 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION (US) | 2023-11-09 | — | — | WO | disclosed |
| US-10329575-B2 | Regulatory sequence for plants | CERES, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180223303-A1 | SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY | CERES INC (US) | 2018-08-09 | — | — | US | disclosed |
| WO-2017173975-A1 | METHOD FOR SYNTHESIZING COMPOUND CONTAINING NON-TERMINAL DOUBLE BOND | 中国科学院福建物质结构研究所 | 2017-10-12 | — | — | WO | disclosed |
| EP-2875023-B1 | OCTAHYDRO-CYCLOPENTAPYRROLYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-05 | — | — | EP | disclosed |
| US-20170037426-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | ALEXANDROV NICKOLAI (US) | 2017-02-09 | — | — | US | disclosed |
| US-20160076046-A1 | PROMOTER, PROMOTER CONTROL ELEMENTS, AND COMBINATIONS, AND USES THEREOF | CERES, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9029523-B2 | Promoter, promoter control elements, and combinations, and uses thereof | CERES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9024017-B2 | Octahydro-cyclopentapyrrolyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-05 | — | — | US | disclosed |
| US-20120159672-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | CERES, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120084885-A1 | Promoter, promoter control elements, and combinations, and uses thereof | ALEXANDROV NICKOLAI (US) | 2012-04-05 | — | — | US | disclosed |
| US-20110191912-A1 | Promoter, promoter control elements, and combinations, and uses thereof | ALEXANDROV NICKOLAI | 2011-08-04 | — | — | US | disclosed |
| US-20100037355-A1 | SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY | CERES, INC (US) | 2010-02-11 | — | — | US | disclosed |
| US-20090265815-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded therapy | ALEXANDROV NICKOLAI | 2009-10-22 | — | — | US | disclosed |
| US-20070214517-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | CERES, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20060150283-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | ALEXANDROV NICKOLAI | 2006-07-06 | — | — | US | disclosed |
| US-20060048240-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | ALEXANDROV NICKOLAI | 2006-03-02 | — | — | US | disclosed |
| EP-0079639-B1 | A NEW ANTI-INFLAMMATORY DRUG | SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A. (IT) | 1985-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037426-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | ALDH1A1 4769/4885FBP1 1716/4885TP53 676/4885 |
| US-20120084885-A1 | Promoter, promoter control elements, and combinations, and uses thereof | RNGTT, GTF3C5, GTF3C1 | ALDH1A1 4633/4885FBP1 1026/4885TP53 846/4885 |
| US-20070214517-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | ALDH1A1 4769/4885FBP1 1716/4885TP53 676/4885 |
| US-20110191912-A1 | Promoter, promoter control elements, and combinations, and uses thereof | RNGTT, GTF3C5, GTF3C1 | ALDH1A1 4635/4885FBP1 1081/4885TP53 871/4885 |
| US-20120159672-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | ALDH1A1 4769/4885FBP1 1716/4885TP53 676/4885 |
| US-20100037355-A1 | SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY | RNGTT, CPSF1, CPSF6 | ALDH1A1 4769/4885FBP1 1716/4885TP53 676/4885 |
| US-20060048240-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | ALDH1A1 4769/4885FBP1 1716/4885TP53 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.